Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.

Naoki Kanomata,Shiro Matsuura,Taisuke Mori,Jo Kitawaki,Takuya Moriya,Tsunehisa Nomura,Junichi Kurebayashi

doi:10.1371/journal.pone.0183202

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0177439.].

Highlights

The correct Abstract is: Aromatase inhibitors have been widely used for the endocrine treatment of estrogen-dependent breast cancer in postmenopausal patients
We have generated a polyclonal antiserum with high affinity and specificity for human aromatase using a monoclonal antibody tagged immunoaffinity chromatography on an industrial production scale
The histoscore for aromatase was inversely correlated with pT (p = 0.019), pN (p = 0.001), stage (p < 0.001), histologic grade (p = 0.003), lymphatic infiltration (p < 0.001), venous infiltration (p < 0.001), and Ki-67 index (p < 0.001)

Summary

Introduction

The correct Abstract is: Aromatase inhibitors have been widely used for the endocrine treatment of estrogen-dependent breast cancer in postmenopausal patients. Clinicopathological studies of aromatase have been limited due to unsatisfactory specificity and/or restricted availability of anti-aromatase antibodies.

Results

Conclusion